Trial Profile

XanaCIDD: a Double-Blind, Randomized, Placebo Controlled, Parallel-Group Trial to Assess the Safety, Tolerability, and Efficacy of Xanamem in Adults with Major Depressive Disorder and Impaired Cognition

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 24 Jan 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

26 Aug 2024 According to an Actinogen Medical media release, company will discuss depression data and trial results findings about Xanamem's cortisol control mechanism in a webinar at 11am (AEST) on Thurs, Aug 29 or 9pm (US ET) on Wed, Aug 28.
26 Aug 2024 Results published in an Actinogen Medical media release
10 Jul 2024 Status changed from active, no longer recruiting to completed.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com